A Multi-Center, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension.

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2015

At a glance

  • Drugs Osilodrostat (Primary) ; Eplerenone
  • Indications Essential hypertension
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Oct 2011 Results published in the Circulation.
    • 16 Mar 2010 Results were presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC-2010).
    • 16 Mar 2010 Primary endpoint 'Diastolic blood pressure' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top